用Cinobufacini和Paclitaxel-Cisplatin组合治疗晚期宫癌:一个元分析
Zixin Chen1, Lu Zhang2, Die Li1
1Mianzhu City People's Hospital, Mianzhu, Sichuan, China.
Medicine
|September 9, 2025
概括
将金诺法西尼添加到帕克利塔塞尔-西斯普拉丁化疗中,显著改善了晚期宫癌的治疗结果. 这种组合提高了反应率,并减少了骨髓抑制和吐等不良影响.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 对于晚期子宫癌的标准帕克利塔塞尔-西斯普拉丁 (TP) 化疗,在有效性和毒性方面面临挑战.
- 传统中医药的Cinobufacini (Huachansu) 是一个有前途的药物,可以增强传统的癌症治疗方法.
研究的目的:
- 系统地评估 cinobufacini 与TP化疗相结合的疗效和安全性,与单独的TP化疗相比,在晚期宫癌中.
- 评估对临床响应率,性能状况和与治疗相关的毒性影响.
主要方法:
- 一个系统的审查和随机对照试验 (RCTs) 的元分析发表到2024年7月30日.
- 包括的研究比较了在晚期宫癌患者中单独使用TP化疗与 cinobufacini + TP化疗.
- 分析的结果包括临床反应率,卡诺夫斯基性能状态 (KPS),骨髓抑制,血小板计数,吐和腹.
主要成果:
- 有814名参与者的6项RCT表明,布法西尼+TP化疗显著改善了临床反应率 (RR 1.22) 和KPS (MD 7.37).
- 组合疗法显著降低了骨髓抑制 (RR 0.53),血小板数量下降 (MD -94.25),吐 (RR 0.58),以及腹 (RR 0.60).
- 敏感性分析证实了研究结果的稳定性,尽管最初的异质性适度.
结论:
- 作为TP化疗的辅助剂,Cinobufacini为晚期宫癌患者提供了显著的好处.
- 它增强了临床结果,并大大减轻了与治疗相关的不良事件.
- 进一步的大规模研究是有必要的,以巩固 cinobufacini 在宫癌治疗方案中的作用.
更多相关视频
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
19.1K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.4K
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
606
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
606
